← Back to Screener
Biodesix, Inc. Common Stock (BDSX)
Price$15.27
Value ScoreD
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)134.76%
Price vs S&P 500 (4W)42.32%
VGM Score63.76
Market Capitalization$164.97M
All Metrics
Book Value / Share (Quarterly)$0.90
P/TBV (Annual)14.84x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)32.31%
Cash Flow / Share (Quarterly)$-2.50
Price vs S&P 500 (YTD)129.07%
Gross Margin (TTM)82.08%
Net Profit Margin (TTM)-33.26%
EPS (TTM)$-4.03
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-4.03
Revenue Growth (5Y)14.20%
EPS (Annual)$-4.67
ROI (Annual)-74.92%
Gross Margin (Annual)81.11%
Net Profit Margin (5Y Avg)-91.35%
Cash / Share (Quarterly)$2.53
Revenue Growth QoQ (YoY)42.30%
ROA (Last FY)-40.31%
Revenue Growth TTM (YoY)29.05%
EBITD / Share (TTM)$-2.37
ROE (5Y Avg)-391.42%
Operating Margin (TTM)-25.95%
Cash Flow / Share (Annual)$-2.87
P/B Ratio18.07x
P/B Ratio (Quarterly)16.05x
Net Income / Employee (Annual)$-105,600
EV / Revenue (TTM)1.93x
Net Interest Coverage (TTM)-3.57x
ROA (TTM)-35.65%
EPS Incl Extra (Annual)$-4.67
Current Ratio (Annual)1.86x
Quick Ratio (Quarterly)2.82x
3-Month Avg Trading Volume0.13M
52-Week Price Return150.69%
Revenue / Employee (TTM)$287,700
Tangible BV / Share (Quarterly)$0.56
P/S Ratio (Annual)1.86x
Asset Turnover (Annual)1.01x
52-Week High$20.21
Operating Margin (5Y Avg)-77.20%
EPS Excl Extra (Annual)$-4.67
CapEx CAGR (5Y)-28.65%
26-Week Price Return150.69%
Quick Ratio (Annual)1.86x
13-Week Price Return14.77%
Total Debt / Equity (Annual)1.75x
Current Ratio (Quarterly)2.82x
Enterprise Value$185.89M
Revenue / Share Growth (5Y)46.86%
Asset Turnover (TTM)1.07x
Revenue / Employee (Annual)$265,000
Pretax Margin (Annual)-39.85%
Cash / Share (Annual)$2.30
3-Month Return Std Dev105.12%
Gross Margin (5Y Avg)67.95%
Net Income / Employee (TTM)$-95,700
ROE (Last FY)-205.65%
Net Interest Coverage (Annual)-3.04x
EPS Basic Excl Extra (Annual)$-4.67
Receivables Turnover (TTM)11.21x
Total Debt / Equity (Quarterly)5.09x
EPS Incl Extra (TTM)$-4.03
Receivables Turnover (Annual)10.03x
ROI (TTM)-37.20%
P/S Ratio (TTM)1.72x
Pretax Margin (5Y Avg)-91.35%
Revenue / Share (Annual)$11.72
Tangible BV / Share (Annual)$2.06
Price vs S&P 500 (52W)122.49%
Year-to-Date Return140.00%
5-Day Price Return9.31%
EPS Normalized (Annual)$-4.67
ROA (5Y Avg)-52.85%
Net Profit Margin (Annual)-39.85%
Month-to-Date Return48.63%
Cash Flow / Share (TTM)$-0.82
EBITD / Share (Annual)$-3.00
Operating Margin (Annual)-31.50%
LT Debt / Equity (Annual)1.74x
ROI (5Y Avg)-107.95%
LT Debt / Equity (Quarterly)5.09x
EPS Basic Excl Extra (TTM)$-4.03
P/TBV (Quarterly)25.80x
P/B Ratio (Annual)10.66x
Pretax Margin (TTM)-33.26%
Book Value / Share (Annual)$2.87
Price vs S&P 500 (13W)5.02%
Beta0.61x
Revenue / Share (TTM)$9.95
ROE (TTM)-375.09%
52-Week Low$5.00
vGradeD
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.81est. -1.12
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.18
4.18
4.18
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BDSXBiodesix, Inc. Common Stock | D | B | A | $15.27 |
| NTRANatera, Inc. Common Stock | F | A | B | $218.81 |
| DGXQuest Diagnostics Inc. | C | D | C | $192.20 |
| LHLabcorp Holdings Inc. | C | D | C | $256.87 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $129.14 |
| CELCCelcuity Inc. Common Stock | — | — | B | $122.96 |
| CAICaris Life Sciences, Inc. Common Stock | F | F | C | $16.45 |
| RDNTRadNet, Inc. Common Stock | D | C | D | $52.89 |
| VCYTVeracyte, Inc. | D | A | B | $48.18 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $64.40 |
About
Biodesix is a lung-focused diagnostic company that provides blood-based testing services for lung cancer and COVID-19. The company generates revenue through two primary channels: direct diagnostic testing services and partnerships with biopharmaceutical companies for clinical trial diagnostics and companion diagnostic development. This dual-revenue model positions Biodesix at the intersection of clinical diagnostics and drug development, creating diverse market opportunities.